<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00219908</url>
  </required_header>
  <id_info>
    <org_study_id>981166</org_study_id>
    <nct_id>NCT00219908</nct_id>
  </id_info>
  <brief_title>Evaluation of a New Therapeutic Strategy in Early and Active Relapsing-Remitting Multiple Sclerosis</brief_title>
  <official_title>Evaluation of a New Therapeutic Strategy in Early and Active Relapsing-Remitting Multiple Sclerosis: Induction Treatment With Mitoxantrone Followed by Long-Term Treatment With Interferon-beta1b</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Farmades, Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rennes University Hospital</source>
  <brief_summary>
    <textblock>
      The aim of the study is to determine whether a therapeutic strategy combining mitoxantrone
      and interferon beta1b can delay disease progression of at least one point on EDSS scale in
      patients with clinically very active relapsing-remitting multiple sclerosis.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>July 1999</start_date>
  <completion_date>June 2006</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to confirmed progression of at least one EDSS point during the 3 years of the study.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>- percentage of patients with confirmed progression of at least one point EDSS (confirmed at 3 and 6 months) during the 3 years of the study,</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- annual rate of relapse;</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- percentage of relapse-free patients during the study period,</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- quality of life,</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- percentage of patients without evidence of disease activity on serial MRIs at months 9, 24 and 36 (number of contrast-enhanced lesions on the annual MRIs, change in lesion burden).</measure>
  </secondary_outcome>
  <enrollment>124</enrollment>
  <condition>Relapsing-Remitting Multiple Sclerosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitoxantrone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age : 18-45 years,

          -  Clinical disease satisfying the Poser criteria (Amdmt n°4)

          -  relapsing-remitting disease (Amdmt N°4)

          -  at least 2 exacerbations within the preceding 12 months, having left sequelae,

          -  MRI activity at inclusion expressed by at least one gadolinium-enhanced lesion
             (cranial MRI with 0.1mmol/kg gadolinium),

          -  a significant disability at inclusion: EDSS score between 2.5 and 5.5 (Amdt N° 4)

          -  written informed consent

        Exclusion Criteria:

          -  pregnancy and breast-feeding

          -  use of an insufficiency effective contraceptive method,

          -  general immunosuppressive therapy using cyclophosphamide, mitoxantrone,or total
             lymphoid irradiation

          -  treatment with azathioprine during the 3 months preceding the study

          -  clinical relapse or intensive corticosteroid treatment within the 30 days preceding
             inclusion,

          -  associated disease (psychiatric disorder, depressive statenot controlled by
             appropriate drug therapy, history of heart disease at inclusion examination
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilles EDAN, Professor</last_name>
    <role>Study Director</role>
    <affiliation>CHU Rennes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Cote de Nacre</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Gabriel Montpied</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Henri Mondor</name>
      <address>
        <city>Creteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Général</name>
      <address>
        <city>Dijon</city>
        <zip>21033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Catholique de Lille</name>
      <address>
        <city>Lomme</city>
        <zip>59462</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pierre Weitheimer Hospital</name>
      <address>
        <city>Lyon</city>
        <zip>69394</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Guy de Chauliac</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Hôpital Central</name>
      <address>
        <city>Nancy</city>
        <zip>54035</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Pitié-Salpétrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Anne</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Fondation Rotschild</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tenon Hospital</name>
      <address>
        <city>Paris</city>
        <zip>759170</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psichiatriche dell'Università di Bari, Policlinico</name>
      <address>
        <city>Bari</city>
        <zip>70122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Scienze Neurologiche e Psichiatriche</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospedal Civile</name>
      <address>
        <city>Gallarate</city>
        <zip>21013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuroriabilitazione dell'Università</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazionz SAN Raffaele del monte tabor</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Neurologica Università di Torino</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2005</study_first_submitted>
  <study_first_submitted_qc>September 16, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>December 21, 2005</last_update_submitted>
  <last_update_submitted_qc>December 21, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 22, 2005</last_update_posted>
  <keyword>Multiple sclerosis</keyword>
  <keyword>Mitoxantrone</keyword>
  <keyword>Methylprednisolone</keyword>
  <keyword>Interferon beta1b</keyword>
  <keyword>Relapse</keyword>
  <keyword>MRI</keyword>
  <keyword>EDSS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Mitoxantrone</mesh_term>
    <mesh_term>Interferon-beta</mesh_term>
    <mesh_term>Interferon beta-1b</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

